These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates. Messier AM; Ohls RK Curr Opin Pediatr; 2014 Apr; 26(2):139-45. PubMed ID: 24535496 [TBL] [Abstract][Full Text] [Related]
6. Darbepoetin Administration in Term and Preterm Neonates. Patel S; Ohls RK Clin Perinatol; 2015 Sep; 42(3):557-66. PubMed ID: 26250917 [TBL] [Abstract][Full Text] [Related]
7. Neuroimaging in former preterm children who received erythropoiesis stimulating agents. Phillips J; Yeo RA; Caprihan A; Cannon DC; Patel S; Winter S; Steffen M; Campbell R; Wiedmeier S; Baker S; Gonzales S; Lowe J; Ohls RK Pediatr Res; 2017 Oct; 82(4):685-690. PubMed ID: 28553989 [TBL] [Abstract][Full Text] [Related]
8. The long-term effect of erythropoiesis stimulating agents given to preterm infants: a proton magnetic resonance spectroscopy study on neurometabolites in early childhood. Gasparovic C; Caprihan A; Yeo RA; Phillips J; Lowe JR; Campbell R; Ohls RK Pediatr Radiol; 2018 Mar; 48(3):374-382. PubMed ID: 29335880 [TBL] [Abstract][Full Text] [Related]
9. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review. Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152 [TBL] [Abstract][Full Text] [Related]
10. Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection. Maxwell JR; Ohls RK Neoreviews; 2019 Nov; 20(11):e622-e635. PubMed ID: 31676737 [TBL] [Abstract][Full Text] [Related]
11. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442 [TBL] [Abstract][Full Text] [Related]
12. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Kiss Z; Elliott S; Jedynasty K; Tesar V; Szegedi J Eur J Clin Pharmacol; 2010 Apr; 66(4):331-40. PubMed ID: 20127232 [TBL] [Abstract][Full Text] [Related]
13. Effect of blood transfusions on cognitive development in very low birth weight infants. Shah P; Cannon DC; Lowe JR; Phillips J; Christensen RD; Kamath-Rayne B; Rosenberg A; Wiedmeier S; Patel S; Winter S; Baker S; Ohls RK J Perinatol; 2021 Jun; 41(6):1412-1418. PubMed ID: 33911186 [TBL] [Abstract][Full Text] [Related]
14. Shift from darbepoetin-α to continuous erythropoietin receptor activator decreases serum aluminium concentration in patients on hemodialysis. Liu WS; Chan HL; Lai YT; Yang YH; Teng HW; Liu CK; Li SY; Yang CY; Liu TY; Lin CC Environ Toxicol Pharmacol; 2016 Jul; 45():108-14. PubMed ID: 27267426 [TBL] [Abstract][Full Text] [Related]
15. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265 [TBL] [Abstract][Full Text] [Related]
16. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. Natalucci G; Latal B; Koller B; Rüegger C; Sick B; Held L; Bucher HU; Fauchère JC; JAMA; 2016 May; 315(19):2079-85. PubMed ID: 27187300 [TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163 [TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-stimulating agents: development, detection and dangers. Franz SE Drug Test Anal; 2009 Jun; 1(6):245-9. PubMed ID: 20355203 [TBL] [Abstract][Full Text] [Related]
19. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator. Yoshida T; Hayashi M Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008 [TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Bennett CL; Silver SM; Djulbegovic B; Samaras AT; Blau CA; Gleason KJ; Barnato SE; Elverman KM; Courtney DM; McKoy JM; Edwards BJ; Tigue CC; Raisch DW; Yarnold PR; Dorr DA; Kuzel TM; Tallman MS; Trifilio SM; West DP; Lai SY; Henke M JAMA; 2008 Feb; 299(8):914-24. PubMed ID: 18314434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]